MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

NCT06367374 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Sonrotoclax
DRUG: Zanubrutinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China